OrbiMed Advisors LLC has demonstrated a net buying bias in recent months, with $29.5 million in total purchases against $18.9 million in sales across 32 transactions involving two companies. The firm’s activity has been concentrated in Sion Therapeutics (SION), where it executed a series of sales totaling $7.9 million between November 2025 and February 2026, including a $4.2 million disposition on November 24, 2025, followed by smaller exits in December and February. However, this selling was offset by significant acquisitions in other holdings. On November 21, 2025, OrbiMed made two separate purchases of Keros Therapeutics (KROS) shares worth $1.3 million and $2.5 million, signaling continued interest in the biotech firm. Earlier activity included a $5 million investment in Adicet Bio (ACET) in October 2025 and a $5.5 million stake in Shattuck Labs (STTK) in August 2025, though the latter involved a mix of purchases and derivative transactions with no reported value. The firm also divested $2.4 million in PMV Pharmaceuticals (PMVP) between September and October 2025. While recent trades show a higher volume of sales (12) compared to buys (8), the dollar-weighted activity leans toward accumulation, particularly in KROS and ACET, suggesting selective positioning rather than a broad retreat.
AI-assisted summary